Positive interim data from Phase III VISTA trial of Vicinium to treat bladder cancer.- Sesen Bio
Sesen Bio reported positive preliminary efficacy data for the primary endpoint of its ongoing Phase III registration trial, the VISTA Trial , of Vicinium for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Gu�rin (BCG) and deemed BCG-unresponsive.
The data reported show clinically meaningful complete response rates in evaluable Carcinoma in situ patients at three, six, nine and 12 months of follow-up in the trial consistent with the data in the completed Phase I and Phase II clinical trials. Importantly, Vicinium continues to be generally well-tolerated in treated patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins